Approxima

Approxima's pitch is narrower than most tools in this space and that's the point. It isn't trying to write your whole test strategy; it's trying to stop your CI from going red for reasons that have nothing to do with your code. Concretely, it debugs flaky Playwright tests and heals broken selectors, and it lets you author tests in plain English instead of hand-maintaining selector paths. The vendor's own framing of the market is the clearest thing on the page: AI browser-use agents are high fidelity but slow and non-deterministic; raw Playwright is fast and somewhat deterministic but low fidelity; Approxima positions itself as high fidelity, deterministic, and fast enough. That's a workload claim, not a capability claim, and it's the claim worth testing against your own suite. The strongest structural feature is the stated independence. Because Approxima is described as a layer on top of Playwright rather than a hosted platform that owns your tests, the vendor says running out of credits or leaving changes nothing — your tests work exactly as they used to, even through the Playwright wrapper. For teams that have watched a QA vendor become a single point of failure, that's the argument that matters most. It also means adoption is low-risk in a way most AI QA platforms aren't: you're adding a repair layer, not migrating a suite. The honest constraints are as clear as the strengths. Approxima is BETA, so you're adopting ahead of general availability. It requires an existing Playwright suite — if your tests live in Cypress, Selenium, or a no-code tool, this isn't for you. And a self-healing layer can only be as good as the failure modes it recognizes; complex business logic and genuinely ambiguous edge cases still need a human. Where it fits: Playwright teams whose CI is noisy, where a meaningful share of red builds are maintenance rather than real defects. Where it doesn't: teams who want to stop owning tests entirely, or who need a fully managed test infrastructure today.